Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Uveal Melanoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Uveal Melanoma - Pipeline Review, H1 2016', provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma - The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects - The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Uveal Melanoma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Uveal Melanoma Overview 9 Therapeutics Development 10 Pipeline Products for Uveal Melanoma - Overview 10 Pipeline Products for Uveal Melanoma - Comparative Analysis 11 Uveal Melanoma - Therapeutics under Development by Companies 12 Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 13 Uveal Melanoma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Uveal Melanoma - Products under Development by Companies 17 Uveal Melanoma - Products under Investigation by Universities/Institutes 18 Uveal Melanoma - Companies Involved in Therapeutics Development 19 Aura Biosciences, Inc. 19 Bellicum Pharmaceuticals, Inc. 20 Celldex Therapeutics, Inc. 21 Cleveland BioLabs, Inc. 22 Eli Lilly and Company 23 Immunocore Limited 24 Navigen Pharmaceuticals, Inc. 25 Novartis AG 26 PEP-Therapy SAS 27 Pfizer Inc. 28 Spectrum Pharmaceuticals, Inc. 29 Uveal Melanoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 AU-011 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 axitinib - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 BPX-701 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 crizotinib - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 DPTC-9h - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 emibetuzumab - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 entolimod - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 glembatumumab vedotin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 IMCgp-100 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 KCN-1 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LXS-196 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 merestinib - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 NAV-2729 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 nutlin-3 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 pasireotide ER - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 sotrastaurin acetate - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 sunitinib malate - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Vaccine 2 for Melanoma - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Vaccine for Oncology - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 vincristine sulfate - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Uveal Melanoma - Recent Pipeline Updates 83 Uveal Melanoma - Dormant Projects 107 Uveal Melanoma - Discontinued Products 108 Uveal Melanoma - Product Development Milestones 109 Featured News & Press Releases 109 Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma 109 Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma 109 Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 110 Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme 111 Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma 111 May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma 112 Appendix 114 Methodology 114 Coverage 114 Secondary Research 114 Primary Research 114 Expert Panel Validation 114 Contact Us 114 Disclaimer 115
List of Tables
Number of Products under Development for Uveal Melanoma, H1 2016 10 Number of Products under Development for Uveal Melanoma - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H1 2016 19 Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 20 Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 21 Uveal Melanoma - Pipeline by Cleveland BioLabs, Inc., H1 2016 22 Uveal Melanoma - Pipeline by Eli Lilly and Company, H1 2016 23 Uveal Melanoma - Pipeline by Immunocore Limited, H1 2016 24 Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 25 Uveal Melanoma - Pipeline by Novartis AG, H1 2016 26 Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2016 27 Uveal Melanoma - Pipeline by Pfizer Inc., H1 2016 28 Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 29 Assessment by Monotherapy Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 35 Number of Products by Stage and Route of Administration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Uveal Melanoma Therapeutics - Recent Pipeline Updates, H1 2016 83 Uveal Melanoma - Dormant Projects, H1 2016 107 Uveal Melanoma - Discontinued Products, H1 2016 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
